Therapeutics Archives - Insight https://www.insightnews.com.au/products/therapeutics/ Presented by Prime Creative Media Fri, 03 Nov 2023 04:36:07 +0000 en-US hourly 1 https://www.insightnews.com.au/wp-content/uploads/2024/02/cropped-Insight-favicon-32x32.png Therapeutics Archives - Insight https://www.insightnews.com.au/products/therapeutics/ 32 32 iTrack six-year data reveals long-term efficacy and safety profile https://www.insightnews.com.au/itrack-six-year-data-reveals-long-term-efficacy-and-safety-profile/ Fri, 03 Nov 2023 04:36:07 +0000 https://www.insightnews.com.au/?p=38237 Nova Eye Medical iTrack Advance six-year data safety efficacy
At the six-year follow up, mean IOP and mean number of medications were significantly reduced.

Adelaide-based Nova Eye Medical has announced the publication of six-year data of its iTrack canaloplasty microcatheter. Published in the Journal of Glaucoma, the data demonstrates its long-termRead More

The post iTrack six-year data reveals long-term efficacy and safety profile appeared first on Insight.

]]> Nova Eye Medical iTrack Advance six-year data safety efficacy
At the six-year follow up, mean IOP and mean number of medications were significantly reduced.
Adelaide-based Nova Eye Medical has announced the publication of six-year data of its iTrack canaloplasty microcatheter. Published in the Journal of Glaucoma, the data demonstrates its long-term
Read More

The post iTrack six-year data reveals long-term efficacy and safety profile appeared first on Insight.

]]> Tapping into ophthalmic opportunities https://www.insightnews.com.au/tapping-into-ophthalmic-opportunities/ Tue, 17 Oct 2023 01:50:36 +0000 https://www.insightnews.com.au/?p=37925
AFT Pharmaceuticals founder and CEO Dr Hartley Atkinson.

The post Tapping into ophthalmic opportunities appeared first on Insight.

]]>
AFT Pharmaceuticals founder and CEO Dr Hartley Atkinson.
AFT Pharmaceuticals is highly selective about the products it brings to the Australasian market – and its eyecare portfolio exemplifies this. CEO Dr Hartley Atkinson discusses the company’s
Read More

The post Tapping into ophthalmic opportunities appeared first on Insight.

]]> Glaukos trials eyelid cream to treat presbyopia and dry eye https://www.insightnews.com.au/glaukos-trials-eyelid-cream-to-treat-presbyopia-and-dry-eye/ Tue, 18 Jan 2022 20:00:08 +0000 https://www.insightnews.com.au/?p=24943
The active ingredient is delivered through the dermis of the eyelid to the eye.

The post Glaukos trials eyelid cream to treat presbyopia and dry eye appeared first on Insight.

]]>
The active ingredient is delivered through the dermis of the eyelid to the eye.
Glaukos has commenced Phase 2 trials of two investigational cream-based drug candidates that are applied to the eyelids to treat dry eye and presbyopia. This month the New York Stock Exchange-listed ophthalmic
Read More

The post Glaukos trials eyelid cream to treat presbyopia and dry eye appeared first on Insight.

]]> Ikervis ciclosporin eye drop now PBS-listed https://www.insightnews.com.au/ikervis-ciclosporin-eye-drop-now-pbs-listed/ Thu, 30 Sep 2021 21:33:14 +0000 https://www.insightnews.com.au/?p=22895 Azura Ophthalmics meibomian gland dysfunction
Published six times per year, Contact Lens Update provides unbiased clinical insights based in current research.

The post Ikervis ciclosporin eye drop now PBS-listed appeared first on Insight.

]]> Azura Ophthalmics meibomian gland dysfunction
Published six times per year, Contact Lens Update provides unbiased clinical insights based in current research.
Pharmaceutical firm Seqirus has announced that its new therapy Ikervis is now available via the Pharmaceutical Benefits Scheme (PBS), making it Australia’s first listed disease modifying ciclosporin
Read More

The post Ikervis ciclosporin eye drop now PBS-listed appeared first on Insight.

]]> New dry eye therapy Cationorm now PBS listed https://www.insightnews.com.au/new-dry-eye-therapy-cationorm-now-pbs-listed/ Tue, 03 Aug 2021 21:13:25 +0000 https://www.insightnews.com.au/?p=21927
Cationorm treats dry eye caused by prolonged use of contact lenses or environmental conditions.

The post New dry eye therapy Cationorm now PBS listed appeared first on Insight.

]]>
Cationorm treats dry eye caused by prolonged use of contact lenses or environmental conditions.
Pharmaceutical company Seqirus has announced that preservative-free dry eye therapy Cationorm is now accessible via the Pharmaceutical Benefits Scheme (PBS) in Australia. The new treatment is a hydrating
Read More

The post New dry eye therapy Cationorm now PBS listed appeared first on Insight.

]]> Prednefrin Forte shortage – TGA approves alternative product https://www.insightnews.com.au/prednefrin-forte-shortage-tga-approves-alternative-product/ Tue, 01 Jun 2021 22:31:40 +0000 http://www.insightnews.com.au/?p=20605 Prednefrin Forte shortage eye drop
The company was alleged to manufacture eye drugs in multi-use bottles, without an adequate preservative.

The post Prednefrin Forte shortage – TGA approves alternative product appeared first on Insight.

]]> Prednefrin Forte shortage eye drop
The company was alleged to manufacture eye drugs in multi-use bottles, without an adequate preservative.
Allergan has secured regulatory approval for an alternative product to address a Prednefrin Forte shortage in Australia. The company confirmed to Insight it had received a Read More

The post Prednefrin Forte shortage – TGA approves alternative product appeared first on Insight.

]]> Prednefrin Forte shortage: supplier working towards providing alternative https://www.insightnews.com.au/prednefrin-forte-shortage-supplier-working-towards-providing-alternative/ Tue, 27 Apr 2021 22:58:27 +0000 http://www.insightnews.com.au/?p=20028
Four cases of enucleation and four deaths are alleged to have occurred from the contaminated drops.

The post Prednefrin Forte shortage: supplier working towards providing alternative appeared first on Insight.

]]>
Four cases of enucleation and four deaths are alleged to have occurred from the contaminated drops.
The Therapeutic Goods Administration (TGA) has confirmed a shortage of Prednefrin Forte 10mL eye drops in Australia, which isn’t expected to be available until January next year, but its supplier
Read More

The post Prednefrin Forte shortage: supplier working towards providing alternative appeared first on Insight.

]]> Clinical trial results reinforce potential new treatment for DME https://www.insightnews.com.au/clinical-trial-results-reinforce-potential-new-treatment-for-dme/ Thu, 17 Dec 2020 01:11:54 +0000 http://www.insightnews.com.au/?p=18461
Novartis is working with regulatory authorities to bring Beovu to DME patients.

The post Clinical trial results reinforce potential new treatment for DME appeared first on Insight.

]]>
Novartis is working with regulatory authorities to bring Beovu to DME patients.
Novartis has announced positive findings from its the Phase 3 trial assessing the efficacy and safety of Beovu (brolucizumab) to treat diabetic macular edema (DME). KESTREL is the second pivotal Phase
Read More

The post Clinical trial results reinforce potential new treatment for DME appeared first on Insight.

]]> Omega-3 dry eye drop arrives in Australia https://www.insightnews.com.au/dry-eye-omega-3-eye-drop-arrives-in-australia/ Mon, 16 Nov 2020 21:00:31 +0000 http://www.insightnews.com.au/?p=17792 NovaTears + Omega-3
NovaTears + Omega-3 was introduced in Australia and New Zealand last year.

The post Omega-3 dry eye drop arrives in Australia appeared first on Insight.

]]> NovaTears + Omega-3
NovaTears + Omega-3 was introduced in Australia and New Zealand last year.
AFT Pharmaceuticals has officially introduced NovaTears + Omega-3 eye drops in Australia, and provided new details about the formulation. Developed in Germany, the therapy is said to be a unique eye lubricant
Read More

The post Omega-3 dry eye drop arrives in Australia appeared first on Insight.

]]> Aussie firm introduces NovaTears +Omega-3 eye drop https://www.insightnews.com.au/aussie-firm-introduces-novatears-omega-3-eye-drop/ Mon, 05 Oct 2020 22:04:55 +0000 http://www.insightnews.com.au/?p=17035
AFT Pharmaceuticals is now supplying NovaTears +Omega-3 to the Australian market.

The post Aussie firm introduces NovaTears +Omega-3 eye drop appeared first on Insight.

]]>
AFT Pharmaceuticals is now supplying NovaTears +Omega-3 to the Australian market.
ASX-listed AFT Pharmaceuticals has expanded its therapeutics range with a new dry eye therapy containing Omega-3. The company has introduced NovaTears +Omega-3, which is now available in addition to the
Read More

The post Aussie firm introduces NovaTears +Omega-3 eye drop appeared first on Insight.

]]>